Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

[1]  C. Obasaju,et al.  A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. , 2011, Critical reviews in oncology/hematology.

[2]  K. Kelly,et al.  Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[4]  E. Gore,et al.  The effects of comorbidity and age on RTOG study enrollment in Stage III non-small cell lung cancer patients who are eligible for RTOG studies. , 2010, International journal of radiation oncology, biology, physics.

[5]  S. Kaasa,et al.  Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. , 2010, European journal of cancer.

[6]  C. Gross,et al.  Predicting chemotherapy toxicity in older adults with cancer: A prospective 500 patient multicenter study. , 2010 .

[7]  G. Lyman,et al.  The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation. , 2010 .

[8]  M. Edelman,et al.  Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Scagliotti,et al.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Maemondo,et al.  Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. , 2010, Annals of Oncology.

[11]  D. Lacombe,et al.  EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Thomas J. Smith,et al.  美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[13]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[14]  M. McKay,et al.  Targeted plasma proteome profiling for early prediction of chemotherapy response and toxicity in colorectal cancer (CRC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Ramalingam,et al.  Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3‐weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer , 2008, Cancer.

[16]  S. Ramalingam,et al.  Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Mohile,et al.  A practical approach to geriatric assessment in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Wildiers,et al.  International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. , 2007, European journal of cancer.

[19]  E. Gore,et al.  Age Is Independent of Comorbidity Influencing Patient Selection for Combined Modality Therapy for Treatment of Stage III Nonsmall Cell Lung Cancer (NSCLC) , 2006, American journal of clinical oncology.

[20]  B. Milleron,et al.  Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  G. Giles,et al.  Increasing underrepresentation of elderly patients with advanced colorectal or non‐small‐cell lung cancer in chemotherapy trials , 2006, Internal medicine journal.

[22]  F. Fossella,et al.  Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first‐line treatment of advanced nonsmall cell lung carcinoma (TAX 326) , 2005, Cancer.

[23]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[24]  G. Hédelin,et al.  Non-small-cell lung cancer in a French department, (1982–1997): management and outcome , 2005, British Journal of Cancer.

[25]  J. Holland,et al.  Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Siu,et al.  Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Rossi,et al.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. , 2003, Journal of the National Cancer Institute.

[29]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[30]  W. Gianni,et al.  Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Hédelin,et al.  Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994 , 2001, British Journal of Cancer.

[32]  A. Gregor,et al.  Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study , 2001, Thorax.

[33]  S. Lichtman,et al.  Pharmacology of antineoplastic agents in older cancer patients. , 2000, Oncology.

[34]  L. Balducci,et al.  The application of the principles of geriatrics to the management of the older person with cancer. , 2000, Critical reviews in oncology/hematology.

[35]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[36]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[37]  G. Lyman,et al.  Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Strauss,et al.  Women and lung cancer: waiting to exhale. , 1997, Chest.

[39]  F. Shepherd,et al.  Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. , 1997, Seminars in oncology.

[40]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[41]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[43]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.